Recent 8-K filings for CARL

• September 30, 2026, 9:15 AM ET leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Carlsmed names Richard Heppenstall CFO as Leo Greenstein departs; FY2026 revenue guidance of $74-$78 million reaffirmed

  Carlsmed appointed Richard Heppenstall, 55, as CFO effective September 28, 2026; he was previously CFO of ZimVie Inc. until its October 2025 acquisition by ArchiMed SAS.

• September 8, 2026, 4:06 PM ET leadership materiality 0.50 neutral item 5.02item 7.01item 9.01

  Carlsmed names Jeffrey Bertolini COO; salary $475k, 50k options granted

  Jeffrey Bertolini, 60, promoted to COO effective September 8, 2026; previously SVP Operational Excellence since March 2025.

• August 5, 2026, 4:05 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Carlsmed Q2 revenue $18.9M (+57% YoY); raises FY2026 guidance to $74-78M

  Revenue $18.9M, up 57% YoY from $12.1M; gross margin 76.8% vs 73.4%.

• June 3, 2026, 4:05 PM ET other materiality 0.10 neutral item 5.07

  Carlsmed shareholders elect two Class I directors, ratify Ernst & Young as auditor

  Niall Casey elected with 19,627,716 votes for (1,352,117 withheld); broker non-votes 4,628,080.

• May 5, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Carlsmed Q1 revenue $16.1M (+58% YoY); raises FY2026 guidance to $72-77M

  Revenue $16.1M, up 58% YoY from $10.2M; gross margin 77.1% vs 74.9%.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Carlsmed Q4 revenue $15.2M (+61% YoY); FY rev $50.5M (+86%); guides FY2026 $70-75M

  Q4 rev $15.2M (+61% YoY), FY rev $50.5M (+86% YoY). Gross margin 76.5% Q4, 75.3% FY.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Carlsmed reports Q4 revenue ~$15.2M (+61% YoY); FY2025 ~$50.5M (+86% YoY)

  Preliminary Q4 2025 revenue of ~$15.2M, 61% increase over Q4 2024.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Carlsmed Q3 revenue $13.1M (up 98% YoY); raises FY2025 guidance to $49M-$50M

  Gross margin expanded to 75.9% from 72.8%; net loss of $8.5M vs $7.8M a year ago.

• October 30, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Carlsmed secures up to $50M credit facility from Customers Bank; $17.5M contingent on revenue milestones

  Term loan of up to $50M ($32.5M immediate, plus $7.5M and $10M upon achieving $60M and $90M trailing revenue milestones) with interest at Prime+0.25% (floor 5.25%).

• August 28, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Carlsmed Q2 revenue $12.1M (+99% YoY); raises FY guidance to $45.5M-$47.5M

  Q2 revenue $12.1M, up 99% YoY; gross margin 73.4%; net loss $6.8M.

• July 24, 2025, 7:59 PM ET other material materiality 1.00 positive item 5.03item 9.01 ◈ Governance Changes ×2

  Carlsmed closes IPO, adopts amended charter and bylaws effective July 24, 2025

  IPO closed on July 24, 2025; amended and restated certificate of incorporation and bylaws effective immediately prior to closing.

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.75 · Most common event earnings

7 positive 0 negative 4 neutral

source · CARL on sec.gov